Huron Consulting Group Elects Dr. L. Thomas Richards to Board

What Happened
Huron Consulting Group (HURN) filed an 8-K reporting that on July 23, 2026 its Board elected Dr. L. Thomas Richards as a director, effective the same date. Dr. Richards will serve until Huron’s 2027 Annual Meeting of Stockholders and will stand for re-election. He was appointed to the Nominating & Corporate Governance, Finance & Capital Allocation, and Technology & Information Security Committees.

Key Details

• Effective date: July 23, 2026; term ends at the 2027 Annual Meeting.
• Committee assignments: Nominating & Corporate Governance; Finance & Capital Allocation; Technology & Information Security.
• Director pay (per company policy): $80,000 annual cash retainer; $7,500 annual retainer for each committee served; $180,000 annual restricted stock grant (Dr. Richards will receive a prorated half grant of $90,000 on Aug 1, 2026, vesting fully one year later). His initial cash retainer will also be prorated.
• Background: Former Chair of WittKieffer’s board; executive roles in life sciences (CEO/interim CEO of One BioMed, TessArae); prior investment banking experience; MD from Harvard Medical School; board service includes Cowen Group and several private and nonprofit boards.
• No related-party arrangements or transactions required to be disclosed under Item 404(a) were reported.

Why It Matters
This 8-K notifies investors of a board composition change and the addition of a director with deep life sciences, healthcare, and financial experience—relevant to Huron’s advisory services and strategic oversight in those sectors. The filing also specifies compensation and vesting timing, which can affect governance and dilution expectations (prorated equity grant of $90,000). The company confirms there are no reportable conflicts or special arrangements tied to the appointment.